# Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

> **NCT02906007** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 54 (actual)

## Conditions studied

- Tuberculosis
- HIV

## Interventions

- **DRUG:** Bedaquiline

## Key facts

- **NCT ID:** NCT02906007
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2024-02-07
- **Final completion:** 2025-04-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906007, "Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02906007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*